[The antitumor activity of liposomal aclarubicin in vitro and in vivo].
Study on antitumor activity of free and liposomal anthracycline antibiotic aclarubicin in vitro and in vivo showed that liposomal aclarubicin was characterised by activity against ascitic Ehrlich carcinoma comparable to that of free aclarubicin when used in a dose of 25 mg/kg. Liposomal antibiotic had a more pronounced antimetastatic action and showed no toxicity (in a dose of 30 mg/kg). Liposomal aclarubicin had a higher activating capacity with respect to the macrophage tumoricidal properties.
Viadro
M M
MM
Navashin
S M
SM
D015250:Aclarubicin / Q000008:administration & dosage* / Q000633:toxicity; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004337:Drug Carriers; D004354:Drug Screening Assays, Antitumor; D004655:Emulsions; D007928:Lethal Dose 50; D007941:Leukemia P388 / Q000188:drug therapy; D008081:Liposomes; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis
D004337:Drug Carriers; D004655:Emulsions; D008081:Liposomes; D015250:Aclarubicin
Protivoopukholevaia aktivnost' liposomal'nogo aklarubitsina in vitro i in vivo.